Study of Concomitant Administration of the sIPV and DTaP or MMR

Phase 4Not Yet RecruitingNCT06920069

Institute of Medical Biology, Chinese Academy of Medical Sciences2,640 enrolled

Overview

This study is a randomized, open-labeled phase IV clinical trial to evaluate the immunogenicity and safety of concomitant administration of sIPV and DTaP or MMR in infants aged 2 months. Primary immunogenicity endpoints in all groups include the seroconversion rate of type I, II, and III anti-poliovirus neutralizing antibodies, anti-DT, anti-TT, anti-PT, anti-FHA, and anti-PRN antibodies 30 days after basic immunization. Secondary immunogenicity endpoints include the seropositive rates, seroconversion rates, geometric mean titer/concentration (GMT/GMC), geometric mean fold increase (GMFI) of type I, II, and III anti-poliovirus neutralizing antibodies, anti-DT, anti-TT, anti-PT, anti-FHA, and anti-PRN antibodies, and anti-measles, anti-mumps, and anti-rubella antibodies 30 days after full immunization. The secondary safety endpoints are the incidence of adverse events (AEs) within 30 minutes after each injection, the incidence of solicited local and systematic AEs in the period of solicitation after each injection, the incidence of unsolicited AEs in 30 days after each injection, the incidence of AEs in 30 days after each injection, and the incidence of serious adverse events in 6 months after administrations.

This is a randomized, open-labeled, parallel phase IV clinical trial to evaluate the immunogenicity and safety of concomitant administration of sIPV and DTaP or MMR. 2640 participants aged 2 months will be randomly assigned to 4 cohorts in a ratio of 1:1:1:1. \[Cohort A\] 660 infants will take administration of sIPV at 2, 3, 4, 18 months of age and DTaP at 2, 4, 6, and 18 months of age. sIPV and DTaP at 2, 4, and 18 months of age will be taken concomitantly. \[Cohort B\] 660 infants will take administration of sIPV at 2, 3 months of age, bOPV at 4 months and 4 years of age, and DTaP at 2, 4, 6, 18 months of age. sIPV/bOPV at 2, 4 months of age will be taken concomitantly. \[Cohort C\] 660 infants will take administration of sIPV at 2, 3, 4, 18 months of age, DTaP at 2, 4, 6, and 18 months of age, and MMR at 18 months of age. DTaP will be taken 7 days after sIPV at 2, 4, 18 months of age. Half participants will take concomitant administration of sIPV and MMR at 18 months of age, and the rest will take them separately (MMR at 19 months of age). \[Cohort D\] 660 infants will take administration of sIPV at 2, 3 months of age, bOPV at 4 months and 4 years of age, and DTaP at 2, 4, 6, 18 months of age. DTaP will be taken 7 days after sIPV/bOPV at 2, 4 months of age. For immunogenicity assessment, blood samples on Day 0 and Day 30 after basic immunization of each kind of investigational vaccine would be collected to evaluate the type I, II, and III anti-poliovirus neutralizing antibodies, anti-DT, anti-TT, anti-PT, anti-FHA, and anti-PRN antibodies, and anti-measles, anti-mumps, and anti-rubella antibodies for different groups. For safety assessment, adverse events after each dose would be recorded through the diary and contact cards by participants' guardians to collect solicited or unsolicited AEs in periods of solicitation and nonsolicitation, respectively. From 31 days after the final dose to 6 months later, serious adverse events will be evaluated by the investigator via phone call or active reports by participants' guardians.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

2,640

Interventions

sIPVBIOLOGICAL

Sabin-strain-based inactivated vaccine (Vero cells), 0.5mL for each dose

DTaPBIOLOGICAL

Adsorbed acellular pertussis, diphtheria and tetanus combined vaccine, 0.5mL for each dose

bOPV 1,3BIOLOGICAL

Poliomyelitis Vaccine Type I Type Ⅲ in Dragee Candy (Human Diploid Cell), Live, 1g for each dose

MMR VaccineBIOLOGICAL

Measles, Mumps and Rubella Combined Live-attenuated Vaccine, 0.5mL for each dose

Eligibility

Sex: ALLMin age: 2 MonthsMax age: 2 MonthsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Age Requirement: Infants aged 2 months at the time of enrollment * Provision of Legal Identification: Volunteers and their legal guardians or appointed representatives must provide valid legal identification documents. * Informed Consent: Legal guardians or appointed representatives of volunteers must have the capacity to understand the informed consent document and the research process, voluntarily participate, and sign the informed consent form. * Adherence: Legal guardians or appointed representatives of volunteers must be able to comply with the requirements in the study as well as complete relevant visits on time. * Birth Condition: Full-term at birth (gestational age ≥ 37 weeks and \< 42 weeks) and birth weight ≥ 2500g Exclusion Criteria: * Vaccination History: received vaccines containing diphtheria-tetanus-pertussis antigens, polio antigens, Hib conjugate vaccine, or 13-valent pneumococcal conjugate vaccine before enrollment. * Those who had received blood transfusions or used blood products (except hepatitis B immunoglobulin) before enrollment. * Recent Vaccination: Volunteers received any inactivated vaccines or subunit vaccines within 7 days (including the 7th day) prior to vaccination with the investigational vaccine, or any other live attenuated vaccines within 14 days (including the 14th day) prior to vaccination. * Acute Illness: Volunteers have experienced acute illnesses (e.g., fever) within 3 days before enrollment, or have used antipyretic analgesics or antihistamines within 3 days. * Allergic History: Volunteers who are allergic to any component of sIPV, bOPV, DTaP, or MMR, or who are allergic to kanamycin sulfate, kanamycin, or gentamicin sulfate, or those with an allergic constitution. * Birth Condition: Severe neonatal diseases caused by abnormal delivery and other reasons, such as birth trauma, neonatal asphyxia, respiratory distress syndrome, neonatal intracranial hemorrhage, etc., or patients with clinically confirmed severe hyperbilirubinemia. * Neurological and Mental Health: Volunteers with encephalopathy, convulsions, epilepsy, or other progressive neurological disorders, or those whose families have a history of genetic predisposition to convulsions or epilepsy, or a history of genetic predisposition to mental illness. * History of Related Illness: Volunteers who have a history of poliomyelitis, pertussis, diphtheria, tetanus, measles, rubella, or mumps. * Immune Therapy: Volunteers with immunodeficiency, weakened immune function, or those who have received immunosuppressive therapy (such as long-term systemic glucocorticoid treatment, but excluding local medications like inhalants or nasal sprays). * Other Diseases: Volunteers with severe diseases, encompassing those in the cardiovascular system, blood and lymphatic systems, immune system, kidneys, liver, gastrointestinal tract, respiratory system, metabolism, and bones, etc. * Participation in Other Clinical Studies: Volunteers are currently or have plans to participate in other clinical studies before enrollment. * Investigator's Discretion: The final exclusion criterion is the investigator's discretion to determine whether a volunteer is suitable for participation in the study.

Locations (9)

Lufeng Center for Disease Control and Prevenion

Chuxiong, Yunnan, China

Yuanmou Center for Disease Control and Prevention

Chuxiong, Yunnan, China

Wuding Center for Disease Control and Prevention

Chuxiong, Yunnan, China

Yaoan Center for Disease Control and Prevention

Chuxiong, Yunnan, China

Lancang Center for Disease Control and Prevention

Puer, Yunnan, China

Yanshan Center for Disease Control and Prevention

Wenshan, Yunnan, China

Qiubei Center for Disease Control and Prevention

Wenshan, Yunnan, China

Guangnan Center for Disease Control and Prevention

Wenshan, Yunnan, China

Mile Center for Disease Control and Prevention

Yisa, Yunnan, China

Outcomes

Primary Outcomes

Immunogenicity index-seroconversion rate of type I anti-poliovirus neutrilizing antibody

Neutralizing antibody assay will be performed using the neutralization method. Seroconversion will be defined as a change from seronegative (\<1:8) to seropositive (≥1:8), or a ≥4-fold increase from baseline

Time frame: Between baseline and day 30 after basic vaccination

Immunogenicity index-seroconversion rate of type II anti-poliovirus neutrilizing antibody

Time frame: Between baseline and day 30 after basic vaccination

Immunogenicity index-seroconversion rate of type III anti-poliovirus neutrilizing antibody

Time frame: Between baseline and day 30 after basic vaccination

Immunogenicity index-seroconversion rate of anti-DT antibody

Antibody assay will be performed using the ELISA method. Seroconversion will be defined as a change from seronegative (Antibody Concentration\<0.1 IU/ml) to seropositive (Antibody Concentration≥0.1 IU/ml), or a ≥4-fold increase from baseline.

Time frame: Between baseline and day 30 after basic vaccination

Immunogenicity index-seroconversion rate of anti-TT antibody

Time frame: Between baseline and day 30 after basic vaccination

Immunogenicity index-seroconversion rate of anti-PT antibody

Antibody assay will be performed using the ELISA method. Seroconversion will be defined as a change from seronegative (Antibody Concentration\<20 IU/ml) to seropositive (Antibody Concentration≥20 IU/ml), or a ≥4-fold increase from baseline.

Time frame: Between baseline and day 30 after basic vaccination

Immunogenicity index-seroconversion rate of anti-FHA antibody

Time frame: Between baseline and day 30 after basic vaccination

Secondary Outcomes

Immunogenicity index-seropositive rate of type I anti-poliovirus neutrilizing antibody

Neutralizing antibody assay will be performed using the neutralization method. Seropositive will be defined as the antibody tie ≥1:8

Time frame: Day 30 after basic vaccination

Immunogenicity index-seropositive rate of type I anti-poliovirus neutrilizing antibody

Neutralizing antibody assay will be performed using the neutralization method. Seropositive will be defined as the antibody tie ≥1:8

Time frame: Day 30 after full vaccination

Immunogenicity index-seropositive rate of type II anti-poliovirus neutrilizing antibody

Neutralizing antibody assay will be performed using the neutralization method. Seropositive will be defined as the antibody tie ≥1:8

Time frame: Day 30 after basic vaccination

Immunogenicity index-seropositive rate of type II anti-poliovirus neutrilizing antibody

Neutralizing antibody assay will be performed using the neutralization method. Seropositive will be defined as the antibody tie ≥1:8

Time frame: Day 30 after full vaccination

Immunogenicity index-seropositive rate of type III anti-poliovirus neutrilizing antibody

Neutralizing antibody assay will be performed using the neutralization method. Seropositive will be defined as the antibody tie ≥1:8

Time frame: Day 30 after basic vaccination

Immunogenicity index-seropositive rate of type III anti-poliovirus neutrilizing antibody

Neutralizing antibody assay will be performed using the neutralization method. Seropositive will be defined as the antibody tie ≥1:8

Time frame: Day 30 after full vaccination

Immunogenicity index-geometric mean titer (GMT) of type I anti-poliovirus neutrilizing antibody

Neutralizing antibody assay will be performed using the neutralization method.

Central Contacts

Jingsi Yang

CONTACT

0871-68334551 yjs@imbcams.com.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Time frame: Day 30 after basic vaccination

Immunogenicity index-geometric mean titer (GMT) of type I anti-poliovirus neutrilizing antibody

Neutralizing antibody assay will be performed using the neutralization method.

Time frame: Day 30 after full vaccination

Immunogenicity index-geometric mean titer (GMT) of type II anti-poliovirus neutrilizing antibody

Neutralizing antibody assay will be performed using the neutralization method.

Time frame: Day 30 after basic vaccination

Immunogenicity index-geometric mean titer (GMT) of type II anti-poliovirus neutrilizing antibody

Neutralizing antibody assay will be performed using the neutralization method.

Time frame: Day 30 after full vaccination

Immunogenicity index-geometric mean titer (GMT) of type III anti-poliovirus neutrilizing antibody

Neutralizing antibody assay will be performed using the neutralization method.

Time frame: Day 30 after basic vaccination

Immunogenicity index-geometric mean titer (GMT) of type III anti-poliovirus neutrilizing antibody

Neutralizing antibody assay will be performed using the neutralization method.

Time frame: Day 30 after full vaccination

Immunogenicity index-geometric mean fold increase (GMFI) of type I anti-poliovirus neutrilizing antibody

Neutralizing antibody assay will be performed using the neutralization method.

Time frame: Between baseline and day 30 after basic vaccination

Immunogenicity index-geometric mean fold increase (GMFI) of type I anti-poliovirus neutrilizing antibody

Neutralizing antibody assay will be performed using the neutralization method.

Time frame: Between baseline and day 30 after full vaccination

Immunogenicity index-geometric mean fold increase (GMFI) of type II anti-poliovirus neutrilizing antibody

Neutralizing antibody assay will be performed using the neutralization method.

Time frame: Between baseline and day 30 after basic vaccination

Immunogenicity index-geometric mean fold increase (GMFI) of type II anti-poliovirus neutrilizing antibody

Neutralizing antibody assay will be performed using the neutralization method.

Time frame: Between baseline and day 30 after full vaccination

Immunogenicity index-geometric mean fold increase (GMFI) of type III anti-poliovirus neutrilizing antibody

Neutralizing antibody assay will be performed using the neutralization method.

Time frame: Between baseline and day 30 after basic vaccination

Immunogenicity index-geometric mean fold increase (GMFI) of type III anti-poliovirus neutrilizing antibody

Neutralizing antibody assay will be performed using the neutralization method.

Time frame: Between baseline and day 30 after full vaccination

Immunogenicity index-seropositive rate of anti-DT antibody

Antibody assay will be performed using the ELISA method. Seropositive will be defined as the antibody concentration≥0.1 IU/ml.

Time frame: Day 30 after basic vaccination

Immunogenicity index-seropositive rate of anti-DT antibody

Antibody assay will be performed using the ELISA method. Seropositive will be defined as the antibody concentration≥0.1 IU/ml.

Time frame: Day 30 after full vaccination

Immunogenicity index-seropositive rate of anti-TT antibody

Antibody assay will be performed using the ELISA method. Seropositive will be defined as the antibody concentration≥0.1 IU/ml.

Time frame: Day 30 after basic vaccination

Immunogenicity index-seropositive rate of anti-TT antibody

Antibody assay will be performed using the ELISA method. Seropositive will be defined as the antibody concentration≥0.1 IU/ml.

Time frame: Day 30 after full vaccination

Immunogenicity index-seropositive rate of anti-PT antibody

Antibody assay will be performed using the ELISA method. Seropositive will be defined as the antibody concentration≥20 IU/ml.

Time frame: Day 30 after basic vaccination

Immunogenicity index-seropositive rate of anti-PT antibody

Antibody assay will be performed using the ELISA method. Seropositive will be defined as the antibody concentration≥20 IU/ml.

Time frame: Day 30 after full vaccination

Immunogenicity index-seropositive rate of anti-FHA antibody

Antibody assay will be performed using the ELISA method. Seropositive will be defined as the antibody concentration≥20 IU/ml.

Time frame: Day 30 after basic vaccination

Immunogenicity index-seropositive rate of anti-FHA antibody

Antibody assay will be performed using the ELISA method. Seropositive will be defined as the antibody concentration≥20 IU/ml.

Time frame: Day 30 after full vaccination

Immunogenicity index-geometric mean concentration (GMC) of antibody against DT